文献速递心脑血管急症重症综合管理与镇静镇痛

动脉瘤性蛛网膜下腔出血的颅内压监测实践、治疗及对结局的影响

Intracranial Pressure Monitoring Practice, Treatment, and Effect on Outcome in Aneurysmal Subarachnoid Hemorrhage.
PubMed 文献 · Neurocrit Care · 2022-12-05
一句话结论在重症动脉瘤性蛛网膜下腔出血患者中,颅内压监测可能与6个月不良神经结局和死亡率降低相关;但瞳孔对光有反应者未见显著获益。

本研究为SYNAPSE-ICU的预设亚组分析,纳入32个国家92个中心的423例动脉瘤性蛛网膜下腔出血患者,其中295例(69.7%)接受颅内压监测。各国颅内压探头置入率差异显著,范围为4.7%~79.9%(中位比值比3.04);颅内压监测中位持续12天,每日中位颅内压值为14 mm Hg,中位最高值为21 mm Hg。接受颅内压监测的患者治疗强度更高(治疗强度水平评分10.33对6.3,p<0.001)。在病情更重的患者中,颅内压监测与更好的6个月结局相关:不良神经结局比值比0.14(95%CI 0.02-0.53,p=0.0113),死亡风险比0.25(95%CI 0.13-0.49,p<0.0001);但双侧瞳孔均有反应的患者中未见显著效应。

要点

  • 32国92中心423例aSAH中,295例(69.7%)置入颅内压探头,各国置入率4.7%~79.9%,中位比值比3.04。
  • 颅内压监测中位持续12天(Q1-Q3 8-18),每日中位颅内压14 mm Hg(Q1-Q3 10-19),中位最高值21 mm Hg(Q1-Q3 16-30)。
  • 监测组治疗强度更高:治疗强度水平评分10.33(标准差3.61)对6.3(标准差4.19),p<0.001。
  • 病情更重者中,颅内压监测与6个月不良神经结局降低相关(OR 0.14,95%CI 0.02-0.53,p=0.0113),死亡风险比0.25(95%CI 0.13-0.49,p<0.0001)。
  • 双侧瞳孔均有反应的患者中,颅内压监测未观察到显著效应。

适用人群与场景

  • 诊断为动脉瘤性蛛网膜下腔出血的患者,来自32个国家92个中心,共423例。
  • 病情更重的患者中观察到颅内压监测与结局的显著关联;双侧瞳孔均有反应的患者中未见显著效应。

处置流程与药物剂量

  • 颅内压监测中位持续12天(Q1-Q3 8-18)。
  • 每日中位颅内压值为14 mm Hg(Q1-Q3 10-19),中位最高值为21 mm Hg(Q1-Q3 16-30)。
  • 颅内压监测患者的治疗强度水平评分中位为10.33(标准差3.61),未监测患者为6.3(标准差4.19),p<0.001。

研究设计与关键结果

  • 研究类型:SYNAPSE-ICU的预设亚组分析,多中心、国际、前瞻性、观察性队列研究。
  • 样本量:423例aSAH患者,来自92个中心、32个国家;295例(69.7%)接受颅内压监测。
  • 主要结果:各国颅内压探头置入率差异显著,范围为4.7%~79.9%(中位比值比3.04)。
  • 在病情更重的患者中,颅内压监测与6个月不良神经结局相关(Glasgow结局扩展评分≤4:OR 0.14,95%CI 0.02-0.53,p=0.0113),与6个月死亡相关(HR 0.25,95%CI 0.13-0.49,p<0.0001)。
  • 双侧瞳孔均有反应的患者中,颅内压监测未观察到显著效应。

证据类型、等级与局限

  • 证据类型:多中心、国际、前瞻性、观察性队列研究的预设亚组分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在病情更重的aSAH患者中,颅内压监测可能与6个月不良神经结局和死亡降低相关(OR 0.14,95%CI 0.02-0.53;HR 0.25,95%CI 0.13-0.49)。
  • 接受颅内压监测的患者接受了更积极的治疗(治疗强度水平评分10.33对6.3,p<0.001)。
  • 双侧瞳孔均有反应的患者中,颅内压监测未见显著获益。
  • 各国颅内压探头置入实践差异大(4.7%~79.9%,中位比值比3.04)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Intracranial pressure (ICP) monitoring and its management in aneurysmal subarachnoid hemorrhage (aSAH) is variable worldwide. The present study aimed to explore the practice of ICP monitoring, its variability across countries, and the association with 6-month outcomes in aSAH.

METHODS: This was a preplanned subanalysis of SYNAPSE-ICU, a multicenter, international, prospective, observational cohort study focused on patients diagnosed with aSAH. We evaluated the variability in ICP monitoring across countries through a logistic regression model adjusted for case-mix and considered countries as a random effect. The association between ICP probe insertion and 6-month mortality and a poor neurological outcome, defined as an Glasgow Outcome Score Extended ≤ 4, was assessed by using a propensity score approach.

RESULTS: A total of 423 patients with aSAH from 92 centers across 32 countries were included in this analysis. ICP monitoring was used in 295 (69.7%) patients. Significant between-country variability in ICP insertion was observed, with an incidence ranging between 4.7% and 79.9% (median odd ratio 3.04). The median duration of ICP monitoring was 12 days (first quartile [Q1] through third quartile [Q3] range 8-18), with an overall daily median ICP value of 14 mm Hg (Q1-Q3 10-19) and a median maximum value of 21 mm Hg (Q1-Q3 16-30). Patients monitored with ICP received more aggressive therapy treatments compared with non-monitored patients (therapy intensity level, TIL, score 10.33 [standard deviation 3.61] vs. 6.3 [standard deviation 4.19], p < 0.001). In more severe patients, ICP monitoring was significantly associated with better 6-month outcome (poor neurological outcome: odds ratio 0.14, 95% confidence interval 0.02-0.53, p = 0.0113; mortality: hazard ratio 0.25, 95% confidence interval 0.13-0.49, p < 0.0001). However, no significant effect was observed in patients with both reactive pupils.

CONCLUSIONS: Our cohort demonstrated high variability in ICP insertion practice among countries. A more aggressive treatment approach was applied in ICP-monitored patients. In patients with severe aSAH, ICP monitoring might reduce unfavorable outcomes and mortality at 6 months.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Baggiani M, Graziano F, Rebora P, et al. Intracranial Pressure Monitoring Practice, Treatment, and Effect on Outcome in Aneurysmal Subarachnoid Hemorrhage. Neurocrit Care. 2022. PMID: 36471182. doi:10.1007/s12028-022-01651-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。